Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Development

Increase in the funding commitment of Néovacs to cover cash requirements through the topline results of the pivotal Phase III clinical study of the drug candidate PXT3003, the PREMIER trial, in development

Related Keywords

United States ,Paris ,France General ,France ,French ,Hugo Brugui ,Hugo Brugi ,Sukaina Virji ,James Kuo ,Joshua Schafer ,Xavier Paoli ,Ghislaine Gasparetto ,Mary Jane Elliott ,Rob Quinn ,Alexandra Harrison ,Investment Group ,Euronext Growth Stock Exchange ,Sciences Po Paris ,Media Relations International ,Investment Committee ,Consilium Strategic Communications ,Euronext ,Charcot Marie Tooth Disease Type ,Global Tech Opportunities ,Chief Executive ,Chief Executive Officer ,Saint Cyr Special Military School ,Managing Director ,Healthcare Ventures ,Pharnext ,Trengthens ,Lies ,Ith ,N 233 Ovacs ,Ecure ,Text ,Steps ,Development ,